Luca Paglialunga

437 total citations
12 papers, 320 citations indexed

About

Luca Paglialunga is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Luca Paglialunga has authored 12 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Luca Paglialunga's work include Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). Luca Paglialunga is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). Luca Paglialunga collaborates with scholars based in Italy, United Kingdom and United States. Luca Paglialunga's co-authors include Biagio Ricciuti, Giulio Metro, Lucio Crinò, Rita Chiari, Francesco Paciullo, Sara Baglivo, Guido Bellezza, Chiara Bennati, Giulia C. Leonardi and F Grignani and has published in prestigious journals such as Frontiers in Oncology, Lung Cancer and Thrombosis Research.

In The Last Decade

Luca Paglialunga

12 papers receiving 316 citations

Peers

Luca Paglialunga
Binliang Liu China
Elisa Sottotetti Italy
Carmen G. Rea Italy
David Ross Camidge United States
Feilong Yang China
Timothy Piers Clackson United States
B.C. Cho South Korea
Leonardo Rojas Colombia
Héctor Aquiles Maldonado-Martínez Mexico
Yunjian Huang China
Binliang Liu China
Luca Paglialunga
Citations per year, relative to Luca Paglialunga Luca Paglialunga (= 1×) peers Binliang Liu

Countries citing papers authored by Luca Paglialunga

Since Specialization
Citations

This map shows the geographic impact of Luca Paglialunga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Paglialunga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Paglialunga more than expected).

Fields of papers citing papers by Luca Paglialunga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Paglialunga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Paglialunga. The network helps show where Luca Paglialunga may publish in the future.

Co-authorship network of co-authors of Luca Paglialunga

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Paglialunga. A scholar is included among the top collaborators of Luca Paglialunga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Paglialunga. Luca Paglialunga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Caliman, Enrico, Francesca Mazzoni, Sara Fancelli, et al.. (2022). Gender Matters. Sex-related Differences in Immunotherapy Outcome in Patients with Non-small Cell Lung Cancer. Current Cancer Drug Targets. 25(1). 64–71. 5 indexed citations
2.
Caliman, Enrico, Sara Fancelli, Francesca Mazzoni, et al.. (2022). Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy. Cancer Treatment and Research Communications. 32. 100603–100603. 17 indexed citations
3.
Fancelli, Sara, Enrico Caliman, Francesca Mazzoni, et al.. (2022). KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population. Frontiers in Oncology. 12. 968064–968064. 5 indexed citations
4.
Paglialunga, Luca, Serena Ricciardi, & M. D’Arcangelo. (2018). New Options on the Horizon for Nononcogene Addicted Non-Small-Cell Lung Cancer. Future Oncology. 14(sup13). 19–28. 3 indexed citations
5.
Ricciuti, Biagio, Sara Baglivo, Luca Paglialunga, et al.. (2017). Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Therapeutic Advances in Medical Oncology. 9(6). 387–404. 29 indexed citations
6.
Mandarano, Martina, Biagio Ricciuti, Rita Chiari, et al.. (2016). Müllerian Tumor Originating from the Pleura in a 47-Years Old Woman: A Case Report. 1(1). 1 indexed citations
7.
Paglialunga, Luca, Zena Salih, Biagio Ricciuti, & Raffaele Califano. (2016). Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?. ESMO Open. 1(4). e000022–e000022. 14 indexed citations
8.
Ricciuti, Biagio, Luca Paglialunga, Francesco Paciullo, et al.. (2016). Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. Medical Oncology. 33(2). 18–18. 122 indexed citations
9.
Bennati, Chiara, Luca Paglialunga, Biagio Ricciuti, et al.. (2016). Targeting EGFR and ALK in NSCLC: Current Evidence and Future Perspective. Europe PMC (PubMed Central). 5(2). 79–90. 1 indexed citations
10.
Ricciuti, Biagio, Giulia C. Leonardi, Giulio Metro, et al.. (2015). Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Review of Respiratory Medicine. 10(1). 53–68. 52 indexed citations
11.
Verso, Melina, Rita Chiari, Stefano Mosca, et al.. (2015). Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. Thrombosis Research. 136(5). 924–927. 35 indexed citations
12.
Chiari, Rita, Giulio Metro, Daniela Iacono, et al.. (2015). Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. Lung Cancer. 90(2). 255–260. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Binliang Liu Breakdown of academic impact, for papers by Elisa Sottotetti Breakdown of academic impact, for papers by Carmen G. Rea Breakdown of academic impact, for papers by David Ross Camidge Breakdown of academic impact, for papers by Feilong Yang Breakdown of academic impact, for papers by Timothy Piers Clackson Breakdown of academic impact, for papers by B.C. Cho Breakdown of academic impact, for papers by Leonardo Rojas Breakdown of academic impact, for papers by Héctor Aquiles Maldonado-Martínez Breakdown of academic impact, for papers by Yunjian Huang
Rankless by CCL
2026